Melanoma Patient Articles & Analysis
7 news found
The Merlin Test identifies melanoma patients that have a low risk for nodal metastasis and therefore can safely forgo a sentinel lymph node biopsy (SLNB) surgery. ...
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients. Dr. Jeffrey S. Weber, Deputy Director of the Laura and Isaac Perlmutter Cancer Center will guide the research and evaluation. ...
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, ...
This approval makes FoundationOne®CDx the only comprehensive genomic profiling (CGP) test approved as a companion diagnostic across two groups of targeted therapies, representing an important step toward simplifying decision making for oncologists. Melanoma is a serious form of skin cancer that accounts for an estimated 207,790 cases each year.1 BRAF mutations are the most ...
Key clinical findings from IMA203 Phase 1a trial In the ongoing ACTengine® IMA203 trial, Immatics is treating advanced solid cancer patients utilizing TCR-T cells directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). ...
The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. It has enabled the Company to identify the first microbiome signature predictive of response to ICI therapy across four independent melanoma studies, by analysing MELRESIST, a melanoma study conducted in collaboration ...
The Microbiotica platform is unrivalled in the comprehensiveness and precision by which it can profile the microbiome of patients. It has enabled the Company to identify the first microbiome signature predictive of response to ICI therapy across four independent melanoma studies, by analysing MELRESIST, a melanoma study conducted in collaboration ...